

# Europe Companion Diagnostics Market: Focus on Application, End User, Technology, and Country - Analysis and Forecast, 2023-2033

<https://marketpublishers.com/r/ED9178326029EN.html>

Date: October 2024

Pages: 0

Price: US\$ 3,250.00 (Single User License)

ID: ED9178326029EN

## Abstracts

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at [order@marketpublishers.com](mailto:order@marketpublishers.com) with your request.

This report will be delivered in 7-10 working days. Introduction to Europe Companion Diagnostics Market

The Europe companion diagnostics market was valued at \$1,116.5 million in 2023 and is expected to reach \$3,562.1 million by 2033, growing at a CAGR of 12.30% between 2023 and 2033. Advances in biomedical imaging, a rise in companion diagnostics product approvals, and the rising prevalence of cancer are driving the companion diagnostics market's expansion in Europe. These elements are major forces behind the region's growing use of companion diagnostics and precision medicine in individualized cancer care.

### Market Introduction

The growing desire for precision medicine and the rising incidence of cancer are driving the companion diagnostics industry in Europe. Particularly in oncology, companion diagnostics are essential for tailoring treatment regimens by identifying patients who are most likely to benefit from particular medicines. Companion diagnostics is a crucial tool for improving treatment outcomes because the increase in cancer incidence throughout Europe has increased the need for such focused medicines.

New companion diagnostics devices are being actively approved by European regulatory bodies, which is driving the market's growth. The market is expanding due to

technological developments in molecular diagnostics, including enhanced biomedical imaging methods and next-generation sequencing (NGS). These developments make it possible to identify biomarkers more precisely, which enables more precisely tailored treatments.

Companion diagnostics are becoming popular not only in oncology but also in other treatment domains as infectious and cardiovascular illnesses. The companion diagnostics market in Europe is anticipated to expand gradually due to rising R&D expenditures and a favorable regulatory framework, expanding the use of customized medicine and boosting patient outcomes throughout the continent.

## Market Segmentation

### Segmentation 1: by Technology

Polymerase Chain Reaction (PCR)

Immunohistochemistry (IHC)

In-Situ Hybridization (ISH)

Next-Generation Sequencing (NGS)

Others

### Segmentation 2: by Application

Lung Cancer

Breast Cancer

Colorectal Cancer

Leukemia

Stomach Cancer

Melanoma

Others

### Segmentation 3: by End User

Pharmaceutical and Biotechnology Companies

Reference Laboratories and Hospitals

Others

### Segmentation 4: by Country

Germany

U.K.

France

Italy

Spain

Rest-of-Europe

How can this report add value to an organization?

**Product/Innovation Strategy:** The Europe companion diagnostics market has been segmented based on various categories, such as technology, application, end user, and country.

**Competitive Strategy:** The Europe companion diagnostics market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the Europe companion diagnostics market analyzed and profiled in the study involve established players that offer various kinds of products and services.

## Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

- bioMérieux
- F. Hoffmann-La Roche Ltd
- ICON Plc
- QIAGEN N.V.

## Contents

Executive Summary  
Scope and Definition

### 1 MARKETS

- 1.1 Trends: Current and Future Impact Assessment
  - 1.1.1 Companion Diagnostics Market Trend Analysis
  - 1.1.2 Implementation of Liquid Biopsy-Based Companion Diagnostics
  - 1.1.3 Combining Artificial Intelligence and Companion Diagnostics
- 1.2 Supply Chain Overview
  - 1.2.1 Value Chain Analysis
- 1.3 Research and Development Review
  - 1.3.1 Patent Filing Trend (by Country, Year)
- 1.4 Regulatory Landscape
  - 1.4.1 Legal Requirements and Framework by the FDA
  - 1.4.2 Legal Requirements and Framework by the EMA
- 1.5 CDx from a Historical Perspective
- 1.6 Constituents for Companion Diagnostics (CDx) Development
- 1.7 Companion Diagnostics (CDx): Future Potential
- 1.8 Market Dynamics Overview
  - 1.8.1 Market Drivers
    - 1.8.1.1 Rising Prevalence of Cancer Cases
    - 1.8.1.2 Increasing Product Approvals in the Field of Companion Diagnostics
    - 1.8.1.3 Advancing Biomedical Imaging as the Driving Force for Precision Medicine's
- Companion Diagnostics
  - 1.8.2 Market Restraints
    - 1.8.2.1 Uncertain Reimbursement Scenario
    - 1.8.2.2 Stringent Regulatory Approval Processes
  - 1.8.3 Market Opportunities
    - 1.8.3.1 Progress in Companion Diagnostics Driven by Continuous Development and Technological Advancements
    - 1.8.3.2 Introduction of Epigenomics-Based Companion Diagnostics

### 2 REGIONS

- 2.1 Regional Summary
- 2.2 Drivers and Restraints

## 2.3 Europe

### 2.3.1 Regional Overview

### 2.3.2 Driving Factors for Market Growth

### 2.3.3 Factors Challenging the Market

### 2.3.4 Application

### 2.3.5 Product

### 2.3.6 France

### 2.3.7 Application

### 2.3.8 Product

### 2.3.9 Germany

### 2.3.10 Application

### 2.3.11 Product

### 2.3.12 U.K.

### 2.3.13 Application

### 2.3.14 Product

### 2.3.15 Spain

### 2.3.16 Application

### 2.3.17 Product

### 2.3.18 Italy

### 2.3.19 Application

### 2.3.20 Product

### 2.3.21 Rest-of-Europe

### 2.3.22 Application

### 2.3.23 Product

## 3 MARKETS - COMPETITIVE BENCHMARKING & COMPANY PROFILES

### 3.1 Next Frontiers.....

### 3.2 Geographic Assessment

#### 3.2.1 bioMérieux

##### 3.2.1.1 Overview

##### 3.2.1.2 Top Products

##### 3.2.1.3 Top Competitors

##### 3.2.1.4 Target Customers

##### 3.2.1.5 Key Personnel

##### 3.2.1.6 Analyst View

#### 3.2.2 F. Hoffmann-La Roche Ltd

##### 3.2.2.1 Overview

##### 3.2.2.2 Top Products/Product Portfolio

- 3.2.2.3 Top Competitors
- 3.2.2.4 Target Customers
- 3.2.2.5 Key Personnel
- 3.2.2.6 Analyst View
- 3.2.3 ICON plc
  - 3.2.3.1 Overview
  - 3.2.3.2 Top Products/Product Portfolio
  - 3.2.3.3 Top Competitors
  - 3.2.3.4 Target Customers
  - 3.2.3.5 Key Personnel
  - 3.2.3.6 Analyst View
- 3.2.4 QIAGEN N.V.
  - 3.2.4.1 Overview
  - 3.2.4.2 Top Products/Product Portfolio
  - 3.2.4.3 Top Competitors
  - 3.2.4.1 Target Customers
  - 3.2.4.2 Key Personnel
  - 3.2.4.3 Analyst View

## **4 RESEARCH METHODOLOGY**

- 4.1 Data Sources
  - 4.1.1 Primary Data Sources
  - 4.1.2 Secondary Data Sources
  - 4.1.3 Data Triangulation
- 4.2 Market Estimation and Forecasts

## List Of Figures

### LIST OF FIGURES

- Figure 1: Europe Companion Diagnostics Market, \$Million, 2023, 2026, and 2033
- Figure 2: Europe Companion Diagnostics Market (by Application), \$Million, 2022, 2026, and 2033
- Figure 3: Europe Companion Diagnostics Market (by Technology), \$Million, 2022, 2026, and 2033
- Figure 4: Europe Companion Diagnostics Market (by End User), \$Million, 2022, 2026, and 2033
- Figure 5: Key Industrial Developments in Companion Diagnostics Market, 2023
- Figure 6: Key Aspects Related to Liquid Biopsy-Based Companion Diagnostics
- Figure 7: Applications of Digital Diagnostics
- Figure 8: Supply Chain and Risks within the Supply Chain
- Figure 9: Europe Companion Diagnostics Market (by Country), January 2021-December 2023
- Figure 10: Europe Companion Diagnostics (by Year), January 2021-December 2023
- Figure 11: Evolution of Companion Diagnostics
- Figure 12: Components Required to Develop Companion Diagnostics
- Figure 13: Future Prospects of CDx
- Figure 14: Impact Analysis of Market Navigating Factors, 2023-2033
- Figure 15: Factors Impacting Reimbursement Scenario
- Figure 16: Advancements in Companion Diagnostics
- Figure 17: Future Outlook of Epigenomics
- Figure 18: Europe Companion Diagnostics Market, \$Million, 2022-2033
- Figure 19: France Companion Diagnostics Market, \$Million, 2022-2033
- Figure 20: Germany Companion Diagnostics Market, \$Million, 2022-2033
- Figure 21: U.K. Companion Diagnostics Market, \$Million, 2022-2033
- Figure 22: Spain Companion Diagnostics Market, \$Million, 2022-2033
- Figure 23: Italy Companion Diagnostics Market, \$Million, 2022-2033
- Figure 24: Rest-of-Europe Companion Diagnostics Market, \$Million, 2022-2033
- Figure 25: Strategic Initiatives, 2021-2023
- Figure 26: Share of Strategic Initiatives, 2021-2023
- Figure 27: Data Triangulation
- Figure 28: Top-Down and Bottom-Up Approach
- Figure 29: Assumptions and Limitations



## List Of Tables

### LIST OF TABLES

Table 1: Market Snapshot

Table 2: Companion Diagnostics Market, Opportunities

Table 3: Some of FDA Approved Liquid Biopsy CDx Tests

Table 4: Cancer Cases Expected between 2020 and 2040

Table 5: Product Approvals in the Field of Companion Diagnostics

Table 6: Companion Diagnostics Preparation (by Region), \$Million, 2022-2033

Table 7: Europe Companion Diagnostics Market (by Application), \$Million, 2022-2033

Table 8: Europe Companion Diagnostics Market (by End User), \$Million, 2022-2033

Table 9: Europe Companion Diagnostics Market (by Technology), \$Million, 2022-2033

Table 10: France Companion Diagnostics Market (by Application), \$Million, 2022-2033

Table 11: France Companion Diagnostics Market (by End User), \$Million, 2022-2033

Table 12: France Companion Diagnostics Market (by Technology), \$Million, 2022-2033

Table 13: Germany Companion Diagnostics Market (by Application), \$Million,  
2022-2033

Table 14: Germany Companion Diagnostics Market (by End User), \$Million, 2022-2033

Table 15: Germany Companion Diagnostics Market (by Technology), \$Million,  
2022-2033

Table 16: U.K. Companion Diagnostics Market (by Application), \$Million, 2022-2033

Table 17: U.K. Companion Diagnostics Market (by End User), \$Million, 2022-2033

Table 18: U.K. Companion Diagnostics Market (by Technology), \$Million, 2022-2033

Table 19: Spain Companion Diagnostics Market (by Application), \$Million, 2022-2033

Table 20: Spain Companion Diagnostics Market (by End User), \$Million, 2022-2033

Table 21: Spain Companion Diagnostics Market (by Technology), \$Million, 2022-2033

Table 22: Italy Companion Diagnostics Market (by Application), \$Million, 2022-2033

Table 23: Italy Companion Diagnostics Market (by End User), \$Million, 2022-2033

Table 24: Italy Companion Diagnostics Market (by Technology), \$Million, 2022-2033

Table 25: Rest-of-Europe Companion Diagnostics Market (by Application), \$Million,  
2022-2033

Table 26: Rest-of-Europe Companion Diagnostics Market (by End User), \$Million,  
2022-2033

Table 27: Rest-of-Europe Companion Diagnostics Market (by Technology), \$Million,  
2022-2033

## I would like to order

Product name: Europe Companion Diagnostics Market: Focus on Application, End User, Technology, and Country - Analysis and Forecast, 2023-2033

Product link: <https://marketpublishers.com/r/ED9178326029EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ED9178326029EN.html>